Insider buys are rising for these three stocks. That includes UnitedHealth Group, whose new CEO with a history of generating returns spent millions on shares.
Abbott’s sales of continuous glucose monitors were $1.9 billion in the second quarter, marking a growth of 21.4% on a reported basis, the company said.
The health insurer now expects its adjusted net income per diluted share to be approximately $30.00, down from its previous guidance of $34.15 to $34.85.
Shares of radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH)
fell 7.7% in the morning session after the stock hit a new 52-week low amid persistent investor concerns over rising competition and the company's recent financial results.
UnitedHealth extended its 15-year earnings beat streak in 2024 with $3.3 billion in asset sales, raising questions about financial reporting and deal transparency.
The healthcare firm is facing renewed scrutiny over its earnings practices and competitive pressures in the pharmacy benefits sector, deepening investor concerns.
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor.
The key risk, however, is that these stocks are usually cheap for a reason – five cents for a piece of fruit may seem like a great deal until you find out it’s rotten.
Shares of biotechnology company Moderna (NASDAQ:MRNA)
fell 3.6% in the morning session after JPMorgan added the stock to its list of top short ideas for the second half of 2025.
Shares of medical supply and logistics company Owens & Minor (NYSE:OMI) fell 3.2% in the morning session after continued pressure from the previous week's announcement of potential new U.S. tariffs on Canada.
NVDA stock hit a $4 trillion market cap, but tariff concerns brought back the bears; next week brings a slew of economic data and the start of earnings season
A number of stocks fell in the afternoon session after the U.S. administration announced a sharp escalation in trade tensions by threatening new tariffs on Canada. The wider market sentiment turned negative after the White House announced plans to impose a 35% tariff on Canadian imports, sparking renewed fears of a trade war. This news prompted a sell-off across major U.S. indexes, including the S&P 500 and the Dow Jones Industrial Average, as investors grew concerned about the potential economic impact of escalating protectionist policies.
The healthcare sector is especially vulnerable to such tensions due to its deeply integrated supply chains with Canada for pharmaceuticals and medical devices, meaning increased costs and potential disruptions.
